Related Experiment Video
Updated: Aug 7, 2026

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
Published on: September 22, 2011
An integrated automated pipeline for cloning, transient expression, and purification augmenting the plant cell pack
Monique Schulze1, Patrick Opdensteinen2, Sandor Albert3
1Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V, Forckenbeckstraße 6, Aachen 52074, Germany; Institute for Molecular Biotechnology, RWTH Aachen University, Worringerweg 1, Aachen 52074, Germany.
Abstract:
Biopharmaceuticals, particularly monoclonal antibodies (mAbs), are a rapidly expanding class of therapeutics and have benefitted from high-throughput screening (HTS) strategies for protein engineering. Obtaining such complex biopharmaceuticals from plants might be advantageous because transient expression can yield grams of product within a week. For HTS, this system was scaled down as plant cell pack (PCP) technology to microtiter plate format and automated on a liquid-handling station, but is limited by manual cloning and protein purification. Therefore, we first generated a modular vector library comprising 15 pTRAc backbone constructs differing in regulatory gene expression and protein targeting elements, enabling rapid integration of any target gene via restriction-ligation cloning. Building on this, we developed an automated, seamless cloning workflow prior to transient expression and integrated a magnetic bead-based downstream purification process for single-chain fragment variable (scFv) mAbs. This automated workflow enables sequential cloning, expression, and purification of up to 375 protein variants simultaneously, each with 10 PCP replicates, within 9 days on a single platform. In contrast, manual processing allows only 15 variants with 10 replicates in the same period - a 25-fold increase in throughput, while costs decreased by 30%, from 79 € to 61 € per variant. Using a recombinant immunotoxin against acute myeloid leukemia based on the anti-CD64 H22 scFv as case study, a recovery of 63% and purity > 95% were obtained, suitable for in vitro assays. Thus, integrating our cloning and purification workflows into the PCP platform establishes an automated pipeline that accelerates early biopharmaceutical development.

